Search

Your search keyword '"Ariga, Takuro"' showing total 145 results
Start Over Author "Ariga, Takuro"
145 results on '"Ariga, Takuro"'

12. Present clinical practices of stereotactic irradiation for metastatic brain tumors in Japan: results of questionnaire survey of the Japanese Radiation Oncology Study Group (JROSG) working subgroup for neurological tumors

Author

Harada, Ken, Igaki, Hiroshi, Abe, Eisuke, Ariga, Takuro, Hayashi, Nobuyuki, Kanemoto, Ayae, Komiyama, Takafumi, Matsumoto, Yasuo, Nakano, Toshimichi, Onimaru, Rikiya, Saito, Hirotake, Sumi, Minako, Tago, Masao, Tanaka, Kensuke, Maebayashi, Katsuya, Aoyama, Hidefumi, and The Japanese Radiation Oncology Study Group (JROSG) Working Subgroup for Neurological Tumors

Published
2018
Full Text
View/download PDF

16. A phase II study of concurrent chemoradiotherapy with 5-fluorouracil and mitomycin-C for squamous cell carcinoma of the anal canal (the JROSG 10–2 trial)

Author

Murofushi, Keiko Nemoto, primary, Itasaka, Satoshi, additional, Shimokawa, Mototsugu, additional, Murakami, Yuji, additional, Yamamoto, Takaya, additional, Nishimura, Yasumasa, additional, Kudo, Shigehiro, additional, Sakamoto, Takashi, additional, Ariga, Takuro, additional, Ogo, Etsuyo, additional, Taguchi, Kentaro, additional, Jingu, Keiichi, additional, and Ogawa, Kazuhiko, additional

Published
2022
Full Text
View/download PDF

18. Definitive radiotherapy consisting of external beam radiotherapy without central shielding and 3D image-guided brachytherapy for patients with cervical cancer: feasibility for Japanese patients and dose–response analyses for local control in the low-dose range

Author

Toita, Takafumi, Wada, Kentaro, Sutani, Shinya, Umezawa, Rei, Maemoto, Hitoshi, Ii, Noriko, Kawamura, Tomoko, Ikushima, Hitoshi, Takenaka, Ryosuke, Konishi, Koji, Yorozu, Atsunori, Jingu, Keiichi, Ariga, Takuro, Nomoto, Yoshihito, and Yamashita, Hideomi

Published
2023
Full Text
View/download PDF

21. A phase II study of concurrent chemoradiotherapy with 5-fluorouracil and mitomycin-C for squamous cell carcinoma of the anal canal (the JROSG 10–2 trial).

Author

Murofushi, Keiko Nemoto, Itasaka, Satoshi, Shimokawa, Mototsugu, Murakami, Yuji, Yamamoto, Takaya, Nishimura, Yasumasa, Kudo, Shigehiro, Sakamoto, Takashi, Ariga, Takuro, Ogo, Etsuyo, Taguchi, Kentaro, Jingu, Keiichi, and Ogawa, Kazuhiko

Subjects
ANUS, SQUAMOUS cell carcinoma, CHEMORADIOTHERAPY, INTENSITY modulated radiotherapy, FLUOROURACIL
Abstract

This study assessed the efficacy of chemoradiotherapy for squamous cell carcinoma of the anal canal (SCCAC). Patients with T1–4N0-3M0 SCCAC received chemoradiotherapy with 5-fluorouracil (5-FU, 800 mg/m2/day, 96-h infusion) and mitomycin-C (MMC, 10 mg/m2 bolus). Patients treated with 3-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiotherapy (IMRT) were administered 36.0 Gy in 20 fractions or 49.5 Gy in 33 fractions for elective nodal irradiation and 59.4 Gy in 33 fractions for primary tumor and metastatic nodal irradiation. The sample size was considered sufficient to estimate 95% confidence intervals (CIs) for the true 2-year disease-free survival (DFS) within a width of +15% when the expected true 2-year DFS was 70%. The primary endpoint was 2-year DFS. The secondary endpoints were 2-year overall survival (OS), locoregional control (LC), colostomy-free survival (CFS) and adverse events. Thirty-one patients were enrolled between January 2014 and July 2019. The median follow-up was 33.3 months (range, 16.2–65.8 months). Among the 31 patients, 13%, 32%, 16% and 39% had stage I, II, IIIA and IIIB disease, respectively. Thirty patients were treated with IMRT. Complete response (CR) was achieved in 27 patients. The 2-year DFS, OS, LC and CFS rates were 77.4% (95% CI, 58.4–88.5%), 93.5% (95% CI, 76.6–98.3%), 83.9% (95% CI, 65.5–92.9%) and 80.6% (95% CI, 61.9–90.8%), respectively. One patient experienced grade 3 late adverse events; however, no grade ≥ 4 late adverse events occurred. Good DFS with a low rate of late adverse events was observed. Chemoradiotherapy with 5-FU and MMC was effective for SCCAC. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

23. Prediction of out-of-field recurrence after chemoradiotherapy for cervical cancer using a combination model of clinical parameters and magnetic resonance imaging radiomics: a multi-institutional study of the Japanese Radiation Oncology Study Group

Author

Ikushima, Hitoshi, primary, Haga, Akihiro, additional, Ando, Ken, additional, Kato, Shingo, additional, Kaneyasu, Yuko, additional, Uno, Takashi, additional, Okonogi, Noriyuki, additional, Yoshida, Kenji, additional, Ariga, Takuro, additional, Isohashi, Fumiaki, additional, Harima, Yoko, additional, Kanemoto, Ayae, additional, Ii, Noriko, additional, Wakatsuki, Masaru, additional, and Ohno, Tatsuya, additional

Published
2021
Full Text
View/download PDF

24. Clinical value of serum biomarkers, squamous cell carcinoma antigen and apolipoprotein C-II in follow-up of patients with locally advanced cervical squamous cell carcinoma treated with radiation: A multicenter prospective cohort study

Author

Harima, Yoko, primary, Ariga, Takuro, additional, Kaneyasu, Yuko, additional, Ikushima, Hitoshi, additional, Tokumaru, Sunao, additional, Shimamoto, Shigetoshi, additional, Takahashi, Takeo, additional, Ii, Noriko, additional, Tsujino, Kayoko, additional, Saito, Anneyuko I., additional, Ushijima, Hiroki, additional, Toita, Takafumi, additional, and Ohno, Tatsuya, additional

Published
2021
Full Text
View/download PDF

25. Therapeutic efficacy of selective intraarterial chemoradiotherapy with docetaxel and nedaplatin for human papilloma virus-negative oropharyngeal cancer

Author

Heianna, Joichi, primary, Makino, Wataru, additional, Hirakawa, Hitoshi, additional, Agena, Shinya, additional, Tomita, Hayato, additional, Ariga, Takuro, additional, Ishikawa, Kazuki, additional, Takehara, Shota, additional, Kusada, Takeaki, additional, Maemoto, Hitoshi, additional, Maeda, Hiroyuki, additional, and Murayama, Sadayuki, additional

Published
2021
Full Text
View/download PDF

26. Small dose of oral gastrografin for computed tomography-based image-guided brachytherapy in patients with uterine cervical cancer

Author

Maemoto, Hitoshi, primary, Ogura, Takuto, additional, Toita, Takafumi, additional, Ariga, Takuro, additional, Hashimoto, Seiji, additional, Kawakami, Yuka, additional, Ishikawa, Kazuki, additional, Takehara, Shota, additional, Heianna, Joichi, additional, Kudaka, Wataru, additional, Aoki, Yoichi, additional, and Nishie, Akihiro, additional

Published
2021
Full Text
View/download PDF

27. Therapeutic efficacy of selective intra-arterial chemoradiotherapy with docetaxel and nedaplatin for fixed bulky nodal disease in head and neck cancer of unknown primary

Author

Heianna, Joichi, primary, Makino, Wataru, additional, Hirakawa, Hitoshi, additional, Agena, Shinya, additional, Tomita, Hayato, additional, Ariga, Takuro, additional, Ishikawa, Kazuki, additional, Takehara, Shota, additional, Maemoto, Hitoshi, additional, and Murayama, Sadayuki, additional

Published
2021
Full Text
View/download PDF

29. Clinical analysis of brachytherapy with permanent iodine-125 seed implantation for organ-confined prostate cancer in 150 patients

Author

Miyazato, Minoru, Ariga, Takuro, Maemoto, Hitoshi, Kusada, Takeaki, Ashikari, Asuka, Uema, Namiko, Miyagi, Ryota, Nakanishi, Shotaro, Goya, Masato, Murayama, Sadayuki, Saito, Seiichi, Department of Urology, Graduate School of Medicine, University of the Ryukyus, and Department of Radiology, Graduate School of Medical Science, University of the Ryukyus

Subjects
brachytherapy, iodine-125, prostate cancer
Abstract

Background: We retrospectively evaluated the outcome of brachytherapy with permanent iodine-125 seed implantation for prostate cancer. Methods: From 2009 to2016, 150 patients（49 in low risk, 81 intermediate, 20 high），mean age 67.1 y, which were performed brachytherapy in our hospital were enrolled in this study. Results: The average prostate volume was 27.4cc, mean International Prostate Symptom Score 9 in these patients. In postplan evaluation, mean prostate V100 93.8%, D90 in brachytherapy alone 173.9Gy, combined with external beam radiation 116.8Gy, rectum V100 in brachytherapy alone 0.27cc, combined with external beam radiation 0.13cc, urethraD90 in brachytherapy alone 89.9Gy, combined with external beam radiation 64.4Gy. The biochemical progression-free survival in 5 years was 97.0% in low risk, while 96.3% in intermediate and no patients in high risk demonstrated PSA relapse during the observation. Migration of seeds was occurred in 3.3%. Adverse event was urinary retention in 2, hematuria in 2, proctitis in 2, rectal bleeding in 2, more than grade 3 was noted in only one patient. Conclusions: The outcome of brachytherapy in our hospital was safe and feasible with low side effects.

Published
2018

30. Indocyanine green fluorescence angiography for detection of cutaneous angiosarcoma of the scalp: A case report

Author

Kusada, Takeaki, primary, Ito, Makoto, additional, Karube, Kennosuke, additional, Shimoji, Shizuki, additional, Oota, Yuka, additional, Zaha, Mayako, additional, Maemoto, Hitoshi, additional, Makino, Wataru, additional, Ishikawa, Kazuki, additional, Takehara, Shota, additional, Ariga, Takuro, additional, Heianna, Joichi, additional, and Murayama, Sadayuki, additional

Published
2020
Full Text
View/download PDF

31. Small dose of oral gastrografin for computed tomography-based image-guided brachytherapy in patients with uterine cervical cancer.

Author

Maemoto, Hitoshi, Ogura, Takuto, Toita, Takafumi, Ariga, Takuro, Hashimoto, Seiji, Kawakami, Yuka, Ishikawa, Kazuki, Takehara, Shota, Heianna, Joichi, Kudaka, Wataru, Aoki, Yoichi, and Nishie, Akihiro

Subjects
HYDROPHILIC compounds, COMPUTED tomography, RADIOISOTOPE brachytherapy
Abstract

Oral administration of a water-soluble iodine contrast agent (gastrografin) was reported to assist in the appropriate contouring of the small intestine on computed tomography (CT)-based radiotherapy (RT) planning. The efficacy and optimal dose of gastrografin in CT-based image-guided brachytherapy (IGBT) for cervical cancer remain unknown. This study aimed to investigate the efficacy of pretreatment oral administration of gastrografin at a small dose of 50 ml in CT-based IGBT for cervical cancer. A total of 422 sessions in 137 patients who underwent CT-based IGBT with 50 ml of oral gastrografin (concentration, 3% or 4%) were analyzed. Preparation of gastrografin was judged as effective when the small intestine was contrast-enhanced at the area where the small intestine was in contact with the uterus/adnexa. About 287 out of 422 sessions (68%) were judged as effective with gastrografin preparation. The 135 ineffective sessions were considered as follows: (i) the contrast enhancement of the small intestine was not confirmed (n = 36), (ii) the small intestine was not in contact with the uterus/adnexa despite the confirmation of the contrast enhancement of the small intestine (n = 34), and (iii) gastrografin was absent in the small intestine at the area in contact with the uterus/adnexa, even when gastrografin was observed in the small intestine at the area not in contact with the uterus/adnexa (n = 65). In conclusion, pretreatment oral administration of a small dose gastrografin achieved moderate efficacy for accurate contouring of the small intestine close to the uterus/adnexa in CT-based IGBT for cervical cancer. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

32. Prediction of out-of-field recurrence after chemoradiotherapy for cervical cancer using a combination model of clinical parameters and magnetic resonance imaging radiomics: a multi-institutional study of the Japanese Radiation Oncology Study Group.

Author

Ikushima, Hitoshi, Haga, Akihiro, Ando, Ken, Kato, Shingo, Kaneyasu, Yuko, Uno, Takashi, Okonogi, Noriyuki, Yoshida, Kenji, Ariga, Takuro, Isohashi, Fumiaki, Harima, Yoko, Kanemoto, Ayae, Ii, Noriko, Wakatsuki, Masaru, and Ohno, Tatsuya

Subjects
CERVICAL cancer, MAGNETIC resonance imaging, CHEMORADIOTHERAPY
Abstract

We retrospectively assessed whether magnetic resonance imaging (MRI) radiomics combined with clinical parameters can improve the predictability of out-of-field recurrence (OFR) of cervical cancer after chemoradiotherapy. The data set was collected from 204 patients with stage IIB (FIGO: International Federation of Gynecology and Obstetrics 2008) cervical cancer who underwent chemoradiotherapy at 14 Japanese institutes. Of these, 180 patients were finally included for analysis. OFR-free survival was calculated using the Kaplan–Meier method, and the statistical significance of clinicopathological parameters for the OFR-free survival was evaluated using the log-rank test and Cox proportional-hazards model. Prediction of OFR from the analysis of diffusion-weighted images (DWI) and T2-weighted images of pretreatment MRI was done using the least absolute shrinkage and selection operator (LASSO) model for engineering image feature extraction. The accuracy of prediction was evaluated by 5-fold cross-validation of the receiver operating characteristic (ROC) analysis. Para-aortic lymph node metastasis (p  = 0.003) was a significant prognostic factor in univariate and multivariate analyses. ROC analysis showed an area under the curve (AUC) of 0.709 in predicting OFR using the pretreatment status of para-aortic lymph node metastasis, 0.667 using the LASSO model for DWIs and 0.602 using T2 weighted images. The AUC improved to 0.734 upon combining the pretreatment status of para-aortic lymph node metastasis with that from the LASSO model for DWIs. Combining MRI radiomics with clinical parameters improved the accuracy of predicting OFR after chemoradiotherapy for locally advanced cervical cancer. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

34. A Phase II Study of Neoadjuvant Chemotherapy Followed by Extended Field Concurrent Chemoradiotherapy for Para-aortic Lymph Node Positive Cervical Cancer

Author

SHIMOJI, YUKO, primary, NAGAI, YUTAKA, additional, TOITA, TAKAFUMI, additional, ARIGA, TAKURO, additional, HEIANNA, JOICHI, additional, NAKASONE, TADAHARU, additional, TAIRA, YUSUKE, additional, ARAKAKI, YOSHIHISA, additional, NAKAMOTO, TOMOKO, additional, OOYAMA, TAKUMA, additional, KUDAKA, WATARU, additional, KANESHIMA, ITOMI, additional, NISHIHIRA, KUMIKO, additional, MEKARU, KEIKO, additional, and AOKI, YOICHI, additional

Published
2020
Full Text
View/download PDF

35. Long-term Outcomes of Cervical Adenocarcinoma Treated With Concurrent Chemoradiotherapy Using Paclitaxel and Cisplatin

Author

ARAKAKI, YOSHIHISA, primary, ARIGA, TAKURO, additional, HEIANNA, JOICHI, additional, SHIMOJI, YUKO, additional, NAKASONE, TADAHARU, additional, TAIRA, YUSUKE, additional, NAKAMOTO, TOMOKO, additional, OOYAMA, TAKUMA, additional, KUDAKA, WATARU, additional, KANESHIMA, ITOMI, additional, NISHIHIRA, KUMIKO, additional, MEKARU, KEIKO, additional, and AOKI, YOICHI, additional

Published
2020
Full Text
View/download PDF

37. Concomitant radiotherapy and transarterial chemoembolization reduce skeletal-related events related to bone metastases from renal cell carcinoma

Author

Heianna, Joichi, primary, Makino, Wataru, additional, Ariga, Takuro, additional, Ishikawa, Kazuki, additional, Kusada, Takeaki, additional, Maemoto, Hitoshi, additional, Toguchi, Masafumi, additional, Ito, Junji, additional, Goya, Masato, additional, Miyazato, Minoru, additional, Iraha, Yuko, additional, and Murayama, Sadayuki, additional

Published
2019
Full Text
View/download PDF

39. Radiation-induced dermatitis after administration of mogamulizumab for adult T-cell leukaemia/lymphoma: a multi-institutional retrospective study

Author

Maemoto, Hitoshi, primary, Ariga, Takuro, additional, Kusada, Takeaki, additional, Heianna, Joichi, additional, Manabe, Yoshihiko, additional, Miyakawa, Akifumi, additional, Nakachi, Sawako, additional, Morishima, Satoko, additional, Iraha, Shiro, additional, Ganaha, Fumikiyo, additional, Masuzaki, Hiroaki, additional, and Murayama, Sadayuki, additional

Published
2018
Full Text
View/download PDF

40. Appropriate radiation dose for symptomatic relief and local control in patients with adult T cell leukemia/lymphoma

Author

Maemoto, Hitoshi, primary, Ariga, Takuro, additional, Nakachi, Sawako, additional, Toita, Takafumi, additional, Hashimoto, Seiji, additional, Heianna, Joichi, additional, Shiina, Hideki, additional, Kusada, Takeaki, additional, Makino, Wataru, additional, Kakinohana, Yasumasa, additional, Miyagi, Takuya, additional, Yamamoto, Yuichi, additional, Morishima, Satoko, additional, Masuzaki, Hiroaki, additional, and Murayama, Sadayuki, additional

Published
2018
Full Text
View/download PDF

41. Computed tomography–based image-guided brachytherapy for cervical cancer: correlations between dose–volume parameters and clinical outcomes

Author

Kusada, Takeaki, primary, Toita, Takafumi, additional, Ariga, Takuro, additional, Maemoto, Hitoshi, additional, Hashimoto, Seiji, additional, Shiina, Hideki, additional, Kakinohana, Yasumasa, additional, Heianna, Joichi, additional, Nagai, Yutaka, additional, Kudaka, Wataru, additional, Aoki, Yoichi, additional, and Murayama, Sadayuki, additional

Published
2017
Full Text
View/download PDF

43. Concurrent weekly cisplatin versus triweekly cisplatin with radiotherapy for locally advanced squamous-cell carcinoma of the cervix: a retrospective analysis from a single institution

Author

Kinjyo, Yoshino, primary, Nagai, Yutaka, additional, Toita, Takafumi, additional, Kudaka, Wataru, additional, Ariga, Takuro, additional, Shimoji, Yuko, additional, Nakasone, Tadaharu, additional, Taira, Yusuke, additional, Arakaki, Yoshihisa, additional, Nakamoto, Tomoko, additional, Wakayama, Akihiko, additional, Ooyama, Takuma, additional, Maemoto, Hitoshi, additional, Heianna, Joichi, additional, and Aoki, Yoichi, additional

Published
2017
Full Text
View/download PDF

46. Appropriate radiation dose for symptomatic relief and local control in patients with adult T cell leukemia/lymphoma.

Author

Maemoto, Hitoshi, Ariga, Takuro, Nakachi, Sawako, Toita, Takafumi, Hashimoto, Seiji, Heianna, Joichi, Shiina, Hideki, Kusada, Takeaki, Makino, Wataru, Kakinohana, Yasumasa, Miyagi, Takuya, Yamamoto, Yuichi, Morishima, Satoko, Masuzaki, Hiroaki, and Murayama, Sadayuki

Subjects
ADULT T-cell leukemia, T-cell lymphoma, CANCER radiotherapy, CANCER remission, CANCER relapse, SKIN inflammation, PALLIATIVE treatment, TREATMENT effectiveness
Abstract

Adult T-cell leukemia/lymphoma (ATL) is an aggressive peripheral T-cell neoplasm that occurs only in patients with human T-cell leukemia virus type 1. No large study or randomized trial investigating radiotherapy (RT) for ATL has been performed. We retrospectively reviewed 55 courses of RT for 41 consecutive patients with ATL who underwent RT between 2000 and 2016 at our institutions. The results showed that RT for local ATL lesions can achieve symptomatic improvement in 92% of cases. Local remission, either complete remission (CR) or partial response (PR), was achieved in 100% of the patients (CR: 89%, PR: 11%) with ≥40 Gy irradiation. CR or PR was achieved in 71% (CR: 29%, PR: 43%) with 30–39 Gy and in 73% (CR: 6.7%, PR: 67%) with ≤29 Gy irradiation. The mean total radiation dose in the CR and PR groups differed significantly (38 vs 25 Gy, P = 0.0002). The maximum acute toxicity was Grade 0–2 in all patients, except for one patient experienced Grade 3 radiation dermatitis. In-field relapses occurred in 36% of patients, and the frequency of in-field relapses was 11%, 30% and 71% among those who achieved CR, PR and SD, respectively. All 9 patients who received total skin irradiation experienced cutaneous relapses, with a median of 63 days (range, 7–210 days). Almost all (39 of 41) patients with ATL experienced out-of-field progression after RT. In conclusion, RT was confirmed to be effective and safe for palliative treatment of local ATL lesions. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

47. Clinical outcomes of radiotherapy for esophageal cancer between 2004 and 2008: the second survey of the Japanese Radiation Oncology Study Group (JROSG)

Author

Nishimura, Yasumasa, primary, Jingu, Keiichi, additional, Itasaka, Satoshi, additional, Negoro, Yoshiharu, additional, Murakami, Yuji, additional, Karasawa, Katsuyuki, additional, Kawaguchi, Gen, additional, Isohashi, Fumiaki, additional, Kobayashi, Masao, additional, Itoh, Yoshiyuki, additional, and Ariga, Takuro, additional

Published
2015
Full Text
View/download PDF

48. Treatment outcomes of patients with FIGO Stage I/II uterine cervical cancer treated with definitive radiotherapy: a multi-institutional retrospective research study

Author

Ariga, Takuro, primary, Toita, Takafumi, additional, Kato, Shingo, additional, Kazumoto, Tomoko, additional, Kubozono, Masaki, additional, Tokumaru, Sunao, additional, Eto, Hidehiro, additional, Nishimura, Tetsuo, additional, Niibe, Yuzuru, additional, Nakata, Kensei, additional, Kaneyasu, Yuko, additional, Nonoshita, Takeshi, additional, Uno, Takashi, additional, Ohno, Tatsuya, additional, Iwata, Hiromitsu, additional, Harima, Yoko, additional, Wada, Hitoshi, additional, Yoshida, Kenji, additional, Gomi, Hiromichi, additional, Numasaki, Hodaka, additional, Teshima, Teruki, additional, Yamada, Shogo, additional, and Nakano, Takashi, additional

Published
2015
Full Text
View/download PDF

49. Computed tomography-based image-guided brachytherapy for cervical cancer: correlations between dose-volume parameters and clinical outcomes.

Author

Kusada, Takeaki, Toita, Takafumi, Ariga, Takuro, Maemoto, Hitoshi, Hashimoto, Seiji, Shiina, Hideki, Kakinohana, Yasumasa, Heianna, Joichi, Nagai, Yutaka, Kudaka, Wataru, Aoki, Yoichi, and Murayama, Sadayuki

Abstract

This study evaluated the oncologic outcomes and complications of cervical cancer patients in terms of CT-based image-guided brachytherapy (IGBT) parameters. Of 68 cervical cancer patients treated with definitive radiotherapy/concurrent chemoradiotherapy, most received whole-pelvis external beam RT (EBRT) of 40 Gy in 20 fractions, pelvic EBRT with central shield of 10 Gy in 5 fractions, and CT-based IGBT of 18 Gy in 3 fractions prescribed to point A. Cumulative EBRT and IGBT doses were calculated as the total equivalent dose in 2 Gy fractions (EQD2). The median follow-up was 31 (3-52) months. The 2-year overall survival, local control, pelvic control, and disease-free survival rates of the 68 patients were 92%, 83%, 82% and 73%, respectively. The HR-CTV D90, length from the tandem axis to left/right margin of the HR-CTV (T-LR), and HR-CTV volume were significant IGBT parameters for predicting local/pelvic control. Patients who received an HR-CTV D90 of >60 Gy, compared with ≤60 Gy, had significantly better local/pelvic control. Furthermore, 70 Gy was a marginally significant HR-CTV D90 cut-off affecting local control. T-LR was an independent IGBT parameter predicting local/pelvic control on multivariate analysis. Three patients developed Grade 3 or higher treatment-related complications. The D2cm3 of organs at risk were not significant predictors of complications. Future challenges for further improving outcomes include additional interstitial needles for irregularly shaped HR-CTVs, and moderate dose escalation, especially for patients with poor tumor responses.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results